The Ingenia Communities Group (ASX: INA) share price is in focus after the company updated investors on a revised acquisition proposal, highlighting continued interest from Warburg Pincus and ongoing progress with Peet Limited.

What did Ingenia Communities Group report?

• Received a further revised non-binding indicative proposal from Warburg Pincus to acquire 100% of Ingenia at $5.25 cash per stapled security.
• The proposal is subject to due diligence and confidentiality arrangements.
• Ingenia is still advancing its acquisition transaction with Peet Limited under the existing scheme implementation deed (SID).
• No determination has been made that the Warburg Pincus proposal is superior or will be recommended to securityholders at this stage.

What else do investors need to know?

Ingenia has granted Warburg Pincus initial due diligence access on a non-exclusive basis, aiming to let Warburg Pincus firm up its offer. Importantly, the Ingenia Board emphasised that there is no certainty the proposal will become a formal binding offer or result in a transaction.

Meanwhile, Ingenia continues with the acquisition by Peet under the terms agreed in August. The Board has put robust governance in place to assess all proposals with a focus on the best interests of Ingenia securityholders. At this stage, investors are advised that no action is needed.

What’s next for Ingenia Communities Group?

Looking ahead, Ingenia will work through its due diligence process with Warburg Pincus and continue progressing the Peet scheme in line with agreed timelines. The Board will assess any revised proposals to ensure decisions serve the interests of all securityholders.

The outcome depends on whether Warburg Pincus’ proposal becomes sufficiently compelling and certain, and on any future recommendations by the Board under the SID with Peet. Investors should stay tuned for further updates.

Ingenia Communities Group share price snapshot

Over the past 12 months, Ingenia shares have declined 14%, trailing the S&P/ASX 200 Index (ASX: XJO), which has fallen 3% over the same period.

View Original Announcement

The post Ingenia Communities Group updates on revised Warburg Pincus offer appeared first on The Motley Fool Australia.

More reading

• Which were the best-performing ASX 200 shares in September?
• Here are the top 10 ASX 200 shares today
• Ingenia Communities receives further revised $5.25 takeover proposal
• Here are the top 10 ASX 200 shares today
• Ingenia Communities rejects revised $5.05 takeover offer

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The CSL Ltd (ASX: CSL) share price is in focus after the company announced an exclusive agreement to co-develop and co-promote lixudebart for rare kidney and liver diseases, with an initial US$355 million payment to Alentis Therapeutics and plans for expanded trials.

What did CSL report?

• Entered exclusive deal with Alentis Therapeutics for lixudebart, a treatment targeting rare kidney and liver conditions
• CSL to make an upfront payment of US$355 million to Alentis
• Additional commercial milestone payments of up to US$1.2 billion possible
• CSL will fund all upcoming Phase 2 and 3 trials for lixudebart in key indications
• Profits from global sales to be shared, with 55% to CSL and 45% to Alentis

What else do investors need to know?

CSL’s new agreement centres around lixudebart, a novel antibody designed to slow both inflammation and fibrosis—key factors in organ damage for conditions like ANCA-associated vasculitis and rapidly progressive glomerulonephritis (AAV-RPGN). Both are life-threatening and currently have limited treatment options.

The company plans to expand clinical trials to cover other rare diseases such as focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC), supporting the growth of CSL’s nephrology portfolio.

What did CSL management say?

Executive Vice President and Head of R&D Dr Bill Mezzanotte said:

We believe lixudebart has the potential to become an important new therapeutic option to help improve kidney function and prevent progression to end-stage kidney disease…Our collaboration with Alentis reflects CSL’s commitment to building a leading global nephrology franchise, and our strategic intent to create high-value external partnerships.

What’s next for CSL?

Looking forward, CSL aims to complete the ongoing Phase 2 clinical trial for lixudebart and start new trials in additional rare kidney and liver diseases. The company’s strategy is to strengthen its position in nephrology through innovation and global partnerships.

Investors can expect further updates as results from these trials are released and as CSL moves closer to potential commercialisation, which would generate shared global profits.

CSL share price snapshot

Over the past 12 months, CSL shares have declined 15%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 3% over the same period.

View Original Announcement

The post CSL unveils exclusive Alentis deal to advance rare disease treatments appeared first on The Motley Fool Australia.

More reading

• Top ASX shares to buy in October 2026
• CSL vs Pro Medicus: Which ASX healthcare share is better?
• Expert names Woodside and CSL shares as top buys today
• What would it take for CSL shares to return to $250?
• Buy, hold, sell: Fortescue, Westpac, CSL shares

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The ASX dividend stock Universe Store Holdings Ltd (ASX: UNI) has fallen 19% from its 2026 high in February 2026, as the chart below shows. I think it’s a great time to invest in the ASX retail share.

Universal Store says it owns a portfolio of premium youth fashion brands. Its principal businesses are Universal Store (trading as Universal Store and Perfect Stranger) and CTC (trading as the THRILLS and Worship brands),

At the last count, it had 123 physical stores across Australia. Its strategy is to grow and develop its premium fashion apparel brands and retail formats, targeting fashion-focused customers.

Higher dividend yield

When a share price changes, it means investors can get a higher dividend yield.

For example, if a business has a dividend yield of 6% and then the share price drops 10%, then the dividend yield becomes 6.6%, which is a big difference for investors wanting dividend income.

As I’ve mentioned, Universal Store’s share price has fallen 19%, significantly boosting the dividend yield.

In FY26, the ASX dividend stock hiked its annual dividend per share by 11.7% to 43 cents per share. That’s currently a grossed-up dividend yield of 8.1%, including franking credits, at the time of writing.

The projection on Commsec suggests the business could hike its annual dividend per share by 4.7% to 45 cents per share. That implies a forward grossed-up dividend yield of 8.4%, including franking credits, at the time of writing.

In terms of passive income, the company is clearly expected to deliver huge payouts.

Ongoing growth

The ASX dividend stock is showing it can deliver growth, even in weak economic conditions. Not many ASX retailers can say that right now.

In FY26, the company generated group sales growth of 12.9% to $376.1 million, with particularly impressive performance by Perfect Stranger which grew sales by 40.8% to $35.9 million.

It also reported that the gross profit margin improved by 140 basis points to 62.5%, and underlying net profit after tax (NPAT) rose by 16.3% to $40.5 million. As you can see, its profit margins rose despite inflation in costs.

FY27 has started strongly and I think this bodes very well for future growth.

In the first seven weeks of FY27, group direct-to-customer sales were up 9.1%, including Perfect Stranger sales growth of 45.8% (partly powered by like-for-like sales growth of 17.6%). Universal Store sales growth was 5.5%, with LFL sales growth of 2.9%.

Management intends to open between 16 and 20 stores in FY27, including nine to ten new Universal Store locations, six to eight new Perfect Stranger stores and one or two new THRILLS stores.

According to the projection on Commsec, the Universal Store share price is valued at 13x FY27’s estimated earnings. I think this is a great time to invest in the ASX dividend stock, though it’s not the only opportunity out there right now.

The post 1 ASX dividend stock down 19% I’d buy right now appeared first on The Motley Fool Australia.

More reading

• Where I’d invest in ASX shares after the recent RBA rate rise
• 2 ASX shares with dividend yields above 8%
• Lovisa vs Universal Store shares: Which ASX retail stock is the better buy today?
• Starting with $20,000, how to build a portfolio generating $5,000 a year in passive income
• 3 excellent ASX dividend shares with 5.5% to 7.7% yields

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Universal Store. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.